These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34774360)

  • 21. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM
    MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
    Nicolay U; Heijnen E; Nacci P; Patriarca PA; Leav B
    Int J Infect Dis; 2019 Aug; 85S():S1-S9. PubMed ID: 30926542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Open-label Randomized Controlled Parallel-group Pilot Study Comparing the Immunogenicity of a Standard-, Double-, and Booster-dose Regimens of the 2014 Seasonal Trivalent Inactivated Influenza Vaccine in Kidney Transplant Recipients.
    Odongo FCA; Braga PE; Palacios R; Miraglia JL; Sartori AMC; Ibrahim KY; Lopes MH; Caiaffa-Filho HH; Timenetsky MDCST; Agena F; Fonseca de Azevedo LS; David-Neto E; Precioso AR; Pierrotti LC
    Transplantation; 2022 Jan; 106(1):210-220. PubMed ID: 33988337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
    Nace DA; Lin CJ; Ross TM; Saracco S; Churilla RM; Zimmerman RK
    J Infect Dis; 2015 Jun; 211(12):1915-24. PubMed ID: 25525051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
    King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
    Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Williams KV; Zhai B; Alcorn JF; Patricia Nowalk M; Levine MZ; Kim SS; Flannery B; Moehling Geffel K; Jaber Merranko A; Nagg JP; Collins M; Susick M; Clarke KS; Zimmerman RK; Martin JM
    Vaccine; 2022 Jan; 40(5):780-788. PubMed ID: 34952751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.
    Gaglani M; Kim SS; Naleway AL; Levine MZ; Edwards L; Murthy K; Dunnigan K; Zunie T; Groom H; Ball S; Jeddy Z; Hunt D; Wesley MG; Sambhara S; Gangappa S; Grant L; Cao W; Gross FL; Mishina M; Fry AM; Thompson MG; Dawood FS; Flannery B
    Clin Infect Dis; 2023 Feb; 76(3):e1168-e1176. PubMed ID: 36031405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
    Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
    Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
    Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study.
    Sundaram ME; Meydani SN; Vandermause M; Shay DK; Coleman LA
    Nutr Res; 2014 Feb; 34(2):149-54. PubMed ID: 24461316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
    Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
    Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
    Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
    Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
    Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
    Teh BW; Leung VKY; Mordant FL; Sullivan SG; Joyce T; Harrison SJ; Khvorov A; Barr IG; Subbarao K; Slavin MA; Worth LJ
    Clin Infect Dis; 2021 Dec; 73(11):e4269-e4277. PubMed ID: 33175132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK; Choi WS; Nowalk MP; Zimmerman RK; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Murthy K; Jackson ML; Jackson LA; Chung JR; Spencer S; Fry AM; Patel M; Flannery B;
    Vaccine; 2020 Sep; 38(42):6562-6569. PubMed ID: 32800465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Chen JY; Hsieh SM; Hwang SJ; Liu CS; Li X; Fournier M; Yeh TY; Yin JK; Samson SI
    Vaccine; 2022 Oct; 40(45):6450-6454. PubMed ID: 36216650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.
    Sarsenbayeva G; Issagulov T; Kassenov M; Abitay R; Orynbayev M; Stukova M; Pisareva M; Davlyatshin T; Lespek K; Khairullin B
    Hum Vaccin Immunother; 2020 Aug; 16(8):1791-1797. PubMed ID: 32048890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.